6 Reasons Why SGMD is Worth More Than $0.20
dispute my
6 Reasons Why SGMD is Worth More Than $0.20
dispute my facts why SGMD worth more than $0.20 – a lot more.
1) There can’t be more than 300MM shares outstanding. The company filed an increase, but announced the cancellation of the meeting yesterday. No meeting = no increase. Good for shareholders.
2) With 300mm shares MAXIMUM the market cap at $0.10 is only $30 million. At $0.15 only $45 mm. Impossible to have dilution above the 30 mm share level without a vote – which was just cancelled. Good for shareholders.
3) They are likely to acquire a revenue stream of more than $30mm in the cannabis space (see the press release and the PR) – add this to SGMD’s revs and it’s at least $37mm a year. At only 1X revenue it’s a $0.123 stock. But, cannabis companies that are growing trade at more than at a LOT MORE than 1X sales. Kush Bottle (KSHB) had revenues of $4.7mm last Q – that’s $19 mm annualized. That means KSHB trades at 11X revenue for a total value of 58million. If we use 11X SGMD revs after the acquisition SGMD market value would be $407 million. This means SGMD would be $1.35 if it trades at a comparable value to KSHB. Good for shareholders, bad if you waited to buy SGMD.
4) Sugarmade will be a lot bigger than KSHB, in fact the largest supplier to the cannabis industry, just in time for California legalization. Good for SGMD shareholders. SGMD is in the think of the Calif legalization with headquarters in LA.
5) SGMD also has the Sriracha relationship. A license agreement with the real Sriracha company - the people with the green cap. www.Srirachastix.com. Read articles on the Internet. Huy Fong Foods rarely license. CEO Chan got a license – what a stud. Good for SGMD shareholders.
6) According to management business is booming at SGMD. The recent SEC filing states relative to the Sriracha products “Sugarmade’s e-commerce capabilities have also recently significantly expand
It's only $, play at ur own risk.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...
Continue Reading
Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...
Continue Reading
A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...
Continue Reading
Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...
Continue Reading
A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...
Continue Reading
Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...
Continue Reading
A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...
Continue Reading
Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...
Continue Reading
Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...
Continue Reading
China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...
Continue Reading
Top 5 Most Recently Viewed Articles
Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.
Continue Reading
Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...
Continue Reading
Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...
Continue Reading
NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...
Continue Reading
Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...
Continue Reading